5th Annual Gene Therapy for Rare Disorders Europe | 2 - 4 November, 2021 | Online

Memo

The 5th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming manufacturing, clinical, and commercialisation challenges drug developers face when delivering gene therapies to market. In the context of unprecedented clinical activity, rapidly approaching approvals and investment at an all-time high, Gene Therapy for Rare Disorders Europe will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve the efficacy, safety and commercial viability of your gene therapy pipeline. Across three content-packed days, this conference will unite leading experts from innovative biotechs, large pharma, academia and key service provider companies, all with the specific focus of solving complex commercial challenges to deliver on the promise of gene therapies for rare disease patients. Wherever you're based, if you're looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward. Date and Time: November 02, 2021 at 8:00 am to November 04, 2021 at 5:00 pm Prices: Drug Developer Rate - Conference + 2 Workshops: GBP 2447.00,Drug Developer Rate - Conference + 1 Workshop: GBP 2148.00,Drug Developer Rate - Conference Only: GBP 1849.00,Standard Rate - Conference + 2 Workshops: GBP 3047.00,Standard Rate - Conference + 1 Workshop: GBP 2698.00,Standard Rate - Conference Only: GBP 2349.00 URLs: Tickets: https://go.evvnt.com/860130-2?pid=5569 Brochure: https://go.evvnt.com/860130-3?pid=5569 Speakers: Rajiv Gangurde, Chief Technical Officer, SparingVision, Simon Hawkins, Senior Clinical Development Director, Orchard Therapeutics, Sven Kili, Principal, Sven Kili Consulting, Magalie Penaud-Budloo, Research Scientist, University of Nantes, Mike Fraser, General Manager Europe, Middle East and Africa, Novartis Gene Therapies, Anne Douar, Chief Development Officer, Vivet Therapeutics, Christina Ohnsman, Senior Clinical Development Lead, REGENXBIO, David Dobnik, Senior Research Associate, NIB, Micheline Wille, Vice President, Medical Affairs EMEA, Novartis Gene Therapies, Nicola Crawford, Director of Analytical Sciences, Orchard Therapeutics, Noam Diamant, Chief Executive Officer, Noga Therapeutics, Magali Taiel, Chief Medical Officer, GenSight Biologics, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, Paul Cox VP, Global Commercial, Freeline Therapeutics, Alexander Natz, Secretary General, EUCOPE, Angela Columbano, Head, Business Development and Partnership, Genethon, Palani Palaniappan, Chief Technical Officer, Aruvant Sciences, Nicholas Medcalf, ISCF Deputy Challenge Director, Medicines Manufacturing, Innovate UK, Paolo Morgese, EU Director Market Access and Member Relations, Alliance for Regenerative Medicine (ARM), Pierre-Albert, Colcomb Business Development Director, Genethon, Craig Martin, Chief Executive Officer, Global Genes, Lucas de Breed, Managing Director, August Care, Michael Linden, Chief Scientific Officer, Handl Therapeutics, Dominique Pichard, Chief Science Officer, International Rett Syndrome Foundation, Esther Attebi, Head of Downstream Process Development, Genethon, Lisa Flint, Founder, AADC Research Trust, Michela Gabaldo, Head of Alliance Management and Regulatory Affairs, Fondazione Telethon, Sheela Upadhyaya, AAC Delivery Lead and HST Specialist, NICE